MiMedx Group Inc  

(Public, NASDAQ:MDXG)   Watch this stock  
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.26 - 11.97
Open     -
Vol / Avg. 0.00/749,842.00
Mkt cap 1.11B
P/E 103.96
Div/yield     -
EPS 0.10
Shares 108.63M
Beta 1.16
Inst. own 43%
Jul 28, 2015
MiMedx Group Inc Annual Shareholders Meeting (Estimated) - 2:00PM EDT - Add to calendar
Jul 27, 2015
Q2 2015 MiMedx Group Inc Earnings Release (Estimated) Add to calendar
May 27, 2015
MiMedx Group Inc at Craig-Hallum Capital Group Institutional Investor Conference Add to calendar
May 14, 2015
MiMedx Group Inc Annual Shareholders Meeting
May 6, 2015
MiMedx Group Inc at Deutsche Bank Health Care Conference - Webcast
Apr 28, 2015
Q1 2015 MiMedx Group Inc Earnings Call - Webcast
Apr 27, 2015
Q1 2015 MiMedx Group Inc Earnings Release
Apr 14, 2015
MiMedx Group Inc at Needham Healthcare Conference - Webcast
Apr 13, 2015
Q1 2015 MiMedx Group Inc Sales Release
Mar 25, 2015
MIMEDX GROUP INC at Regen Med Investor Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 10.03% 5.26%
Operating margin 10.42% 6.01%
EBITD margin - 7.80%
Return on average assets 15.22% 6.41%
Return on average equity 18.66% 7.64%
Employees 386 -
CDP Score - -


1775 W Oak Commons Ct
MARIETTA, GA 30062-2254
United States - Map
+1-678-3846720 (Phone)
+1-678-3846720 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix that are processed from human amniotic membrane that is derived from the donated placentas. MiMedx process the human amniotic membrane utilizing its Purion Process to produce a safe and effective implant. MiMedx is the supplier of amniotic tissue, having supplied hundreds of thousands of allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. The Company’s CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process. The technology is licensed from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Officers and directors

Parker H. Petit Jr. Chairman of the Board, Chief Executive Officer
Age: 75
Bio & Compensation  - Reuters
William Charles Taylor President, Chief Operating Officer, Director
Age: 46
Bio & Compensation  - Reuters
Michael J. Senken Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Alexandra O. Haden General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Charles E. Koob Director
Age: 70
Bio & Compensation  - Reuters
Joseph G. Bleser Independent Director
Age: 69
Bio & Compensation  - Reuters
J. Terry Dewberry Independent Director
Bio & Compensation  - Reuters
Charles R. Evans Independent Director
Age: 68
Bio & Compensation  - Reuters
Bruce L. Hack Independent Director
Age: 66
Bio & Compensation  - Reuters